Investor Relations

VBL Therapeutics to Report Second Quarter 2017 Results on August 14

August 02, 2017

TEL AVIV, Israel, Aug. 02, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Monday, August 14, 2017 at 8:30am Eastern Time to report second quarter ended June 30, 2017 financial results.

Monday, August 14th @ 8:30am Eastern Time
Domestic:   877-280-1254
International:   646-254-3367
Conference ID:   1065636
Webcast:   https://edge.media-server.com/m6/p/m9onohwh

About VBL  
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >200 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).

INVESTOR CONTACT:
Michael RiceLifeSci Advisors, LLC
(646) 597-6979

Primary Logo